title: Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.
abstract: CIGB-300 is a proapoptotic peptide-based drug that abrogates the CK2-mediated phosphorylation. This peptide has antineoplastic effect on lung cancer cells in vitro and in vivo. To understand the mechanisms involved on such anticancer activity, the NCI-H125 cell line proteomic profile after short-term incubation (45 min) with CIGB-300 was investigated. As determined by 2-DE or 2D-LC-MS/MS, 137 proteins changed their abundances more than 2-fold in response to the CIGB-300 treatment. The expression levels of proteins related to ribosome biogenesis, metastasis, cell survival and proliferation, apoptosis, and drug resistance were significantly modulated by the presence of CIGB-300. The protein translation process was the most affected (23% of the identified proteins). From the proteome analysis of the NCI-H125 cell line, novel potentialities for CIGB-300 as anticancer agent were evidenced.
authors.affiliation: Department of Bioinformatics, Center for Genetic Engineering and Biotechnology, Havana, Cuba. arielis.rodriguez@biocomp.cigb.edu.cu
authors.forename: Arielis
authors.initials: A
authors.lastname: Rodríguez-Ulloa
authors.forename: Yassel
authors.initials: Y
authors.lastname: Ramos
authors.forename: Jeovanis
authors.initials: J
authors.lastname: Gil
authors.forename: Yasser
authors.initials: Y
authors.lastname: Perera
authors.forename: Lila
authors.initials: L
authors.lastname: Castellanos-Serra
authors.forename: Yairet
authors.initials: Y
authors.lastname: García
authors.forename: Lázaro
authors.initials: L
authors.lastname: Betancourt
authors.forename: Vladimir
authors.initials: V
authors.lastname: Besada
authors.forename: Luis J
authors.initials: LJ
authors.lastname: González
authors.forename: Jorge
authors.initials: J
authors.lastname: Fernández-de-Cossio
authors.forename: Aniel
authors.initials: A
authors.lastname: Sanchez
authors.forename: Joem M
authors.initials: JM
authors.lastname: Serrano
authors.forename: Hernán
authors.initials: H
authors.lastname: Farina
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Alonso
authors.forename: Boris E
authors.initials: BE
authors.lastname: Acevedo
authors.forename: Gabriel
authors.initials: G
authors.lastname: Padrón
authors.forename: Alexis
authors.initials: A
authors.lastname: Musacchio
authors.forename: Silvio E
authors.initials: SE
authors.lastname: Perea
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002853:Chromatography, Liquid; D016000:Cluster Analysis; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D013058:Mass Spectrometry; D010456:Peptides, Cyclic / Q000494:pharmacology*; D014176:Protein Biosynthesis / Q000187:drug effects*; D020543:Proteome / Q000032:analysis* / Q000145:classification; D040901:Proteomics / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D020543:Proteome; C532510:CIGB-300